Low dose Mounjaro: what the starting doses actually do

Why does Mounjaro start at such a low dose?

A question our prescribers hear most weeks: "Will 2.5 mg actually do anything?" The honest answer is that it does plenty, just not primarily in the weight-loss column. Mounjaro is a dual GIP and GLP-1 receptor agonist, activating two gut-hormone pathways that slow gastric emptying, dampen appetite and influence blood-sugar regulation. Those effects, even at 2.5 mg, can prompt nausea, loose stools or indigestion as your gut adapts. The starter dose exists specifically to reduce that adaptation burden.

The NHS medicines page for tirzepatide describes 2.5 mg as the introductory dose and is clear that the prescriber adjusts the dose over time. The prescribing schedule (confirmed in the Mounjaro SmPC on the eMC) moves in 2.5 mg increments at intervals of at least four weeks. How far and how fast you travel through those steps depends on tolerability and clinical response, not on a fixed timetable.

One misconception worth addressing gently: some people arrive believing that a low dose means a weak medicine or a diluted version of the treatment. It is neither. You are taking the same dual-agonist molecule at every dose; only the quantity changes, and the early steps are there to protect you, not to hold you back.

Can a low dose of Mounjaro produce any weight loss?

Yes, though the magnitude grows with the dose. In the SURMOUNT-1 trial (one of the largest tirzepatide studies, involving 2,539 adults with obesity over 72 weeks) participants on 15 mg achieved around 20–21% average body-weight reduction. Lower doses in the same programme produced smaller but still clinically meaningful reductions. The trial was published in the New England Journal of Medicine and underpinned NICE's recommendation of tirzepatide (TA1026).

What this means practically: someone who can only tolerate 5 mg long-term is likely to see less weight loss than someone who reaches 15 mg, but they are still on an active, licensed, evidence-based treatment. The right dose is the highest you tolerate, not the highest that exists. If you want to explore what the Mounjaro 5 mg dose delivers in practice, our dedicated guide covers that step specifically.

For context on what the full titration journey involves from first pen to maintenance, our overview of the Mounjaro dosing schedule sets out each step alongside what to expect at each stage.

Who might stay on a low dose of Mounjaro longer term?

The licensed schedule is a framework, not a contract. Some people move through 2.5 mg and 5 mg quickly with minimal side effects. Others need more time, particularly if nausea, diarrhoea or fatigue are noticeable after a dose increase. In those cases, staying at the current dose for an additional four weeks (or longer, per prescriber judgement) is entirely appropriate clinical practice.

The question of whether someone can remain on a low dose of Mounjaro indefinitely (rather than continuing to titrate) is worth exploring properly. This page on staying at a low Mounjaro dose looks at what the evidence and guidance say about long-term low-dose use, and if you are specifically weighing up whether the 5mg dose could work as a longer-term option, that guide goes into the detail of how this particular step performs in practice. It is a more nuanced question than it first appears.

People with certain sensitivities (to GI side effects especially) may find a lower maintenance dose is the practical ceiling. The prescriber weighs that against the degree of clinical benefit at that dose. There is no single right answer, which is exactly why these medicines require ongoing prescriber review rather than a one-time sign-off.

What does getting a low-dose Mounjaro prescription actually involve?

Mounjaro is a prescription-only medicine in the UK, which means a prescriber must assess your medical history, current medicines, BMI and any weight-related conditions before any dose is issued. The licensed eligibility threshold is a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. If you have questions about what private treatment costs, the weight-loss treatment overview sets out the options and what is included in the price. For a broader picture of tirzepatide at the starting doses and how it compares to related medicines, the guide to low-dose tirzepatide is a useful companion read.

If you are ready to find out whether Mounjaro is clinically suitable for you, start your free consultation and a prescriber will review your answers the same day.